RAD5 Antibody

What is rAd5 and how is it used as a vector in vaccine development?

Recombinant adenovirus type 5 (rAd5) is a modified adenovirus used as a viral vector to deliver vaccine antigens. In HIV vaccine development, rAd5 vectors have been engineered to express HIV-1 proteins such as Env, Gag, Pol, and Nef. These vectors are replication-defective but can efficiently infect human cells, leading to expression of the encoded antigens and subsequent immune responses .

The rAd5 vector has been extensively used in vaccine studies due to its ability to induce both cellular and humoral immune responses. Beyond HIV, this platform has been explored for vaccines against other pathogens including Plasmodium falciparum, Leishmania, Trypanosoma cruzi, dengue virus, influenza, and Ebola .

What are the primary immune responses measured in rAd5 vaccine trials?

rAd5 vaccine trials typically measure several key immune parameters:

• Antibody responses: These are quantified using enzyme-linked immunosorbent assays (ELISA) to detect binding antibodies against vaccine antigens. For HIV vaccines, antibodies against envelope proteins (Env) from different clades are commonly measured .

• T cell responses: These are assessed using interferon-gamma (IFN-γ) ELISpot assays to measure antigen-specific T cell activation, as well as intracellular cytokine staining to differentiate CD4+ and CD8+ T cell responses .

• Neutralizing antibodies: Both against the vector (Ad5) and target pathogen (e.g., HIV) .

The magnitude and quality of these immune responses, particularly HIV-specific CD4+ and CD8+ T cells and Env-specific antibodies, are considered critical parameters for evaluating vaccine candidates .

How does pre-existing immunity to adenovirus affect rAd5 vaccine efficacy?

Pre-existing immunity to adenovirus type 5, typically measured by Ad5-specific neutralizing antibodies, can impact the immunogenicity of rAd5-based vaccines. Research has shown that:

Despite these effects, research indicates that homologous boosting with rAd5 vectors can still boost antibody responses against the target antigen regardless of pre-existing vector immunity or the interval between prime and boost .

What safety profile has been observed for rAd5 vector vaccines?

rAd5 vector vaccines have demonstrated a generally favorable safety profile in clinical trials. Key safety observations include:

• Local reactogenicity: Common but typically mild to moderate reactions at the injection site, including pain/tenderness, swelling, and redness .

• Systemic reactogenicity: Solicited parameters include malaise, myalgia, headache, chills, nausea, and fever. These are generally mild to moderate and self-limiting .

• Serious adverse events: Rare in clinical trials and typically not attributed to the vaccine .

Safety assessments in trials include self-reported reactogenicity on diary cards (usually for 5 days post-vaccination), clinical follow-up, laboratory monitoring, and documentation of adverse events throughout the study period .

How do DNA prime-rAd5 boost regimens compare to single-dose rAd5 vaccination?

The DNA prime-rAd5 boost approach has been a significant strategy in HIV vaccine development. Comparative findings include:

• Immunogenicity: The DNA/rAd5 prime-boost regimen generally induces stronger and more durable immune responses compared to single-dose rAd5 vaccination. This regimen was designed to elicit "HIV-specific, multifunctional responses in CD4+ and CD8+ T cells and antibodies to envelopes of the major circulating strains" .

• Study design: In the HVTN 505 trial, the 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and Env proteins from clades A, B, and C) was administered at weeks 0, 4, and 8, followed by the rAd5 vector boost at week 24 .

• Efficacy outcome: Despite immunogenicity, the HVTN 505 trial showed that "the DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied" . This highlights the complex relationship between measurable immune responses and protective efficacy.

These findings underscore the importance of testing vaccine regimens in efficacy trials despite promising immunogenicity data in early-phase studies.

What methodological approaches are used to assess T-cell and antibody responses to rAd5 vaccines?

Sophisticated immunological assays are used to evaluate immune responses to rAd5 vaccines:

• T cell response assessment:

  • IFN-γ ELISpot assays to enumerate antigen-specific T cells

  • Intracellular cytokine staining (ICS) to characterize CD4+ and CD8+ T cell responses

  • Flow cytometry to assess multifunctional T cell responses (producing multiple cytokines)

• Antibody response assessment:

  • ELISA to measure binding antibodies against vaccine antigens (e.g., HIV Env proteins)

  • Neutralizing antibody assays to evaluate functional antibody responses

  • Antibody avidity assays to measure the strength of antibody binding

• Timing of assessments: Immune responses are typically measured at multiple timepoints post-vaccination, with peak responses often assessed 2-4 weeks after immunization. For viral load set point assessment in breakthrough infections, measurements are taken at 10, 12, 14, 16, and 20 weeks after HIV diagnosis and averaged .

These methodologies allow researchers to comprehensively characterize the quality, magnitude, and durability of vaccine-induced immune responses.

How does the interval between prime and boost immunizations affect immune responses in rAd5-based vaccines?

The timing between prime and boost immunizations can significantly impact vaccine-induced immune responses. Research findings indicate:

• In studies evaluating homologous rAd5 boosting, participants had received their previous dose of rAd5 at varying intervals ranging from 462 days (66 weeks) to 1772 days (253 weeks) .

• Remarkably, comparable boosting of Env-specific antibody titers was observed regardless of the interval between prime and boost .

• This observation suggests that rAd5-induced immune memory is durable and can be effectively recalled with a booster dose even after a prolonged interval .

This finding has important implications for vaccination strategies, indicating flexibility in scheduling booster doses without compromising immunogenicity. It also suggests that vaccine-induced memory B cells specific for the insert antigens persist long-term and can be effectively restimulated.

What are the immunological differences between needle/syringe delivery versus needle-free (Biojector) delivery of rAd5 vaccines?

Different delivery methods for rAd5 vaccines have been evaluated to optimize immunogenicity:

• Immunogenicity comparison:

  • Studies compared intramuscular (IM) injection via needle and syringe (N/S) versus needle-free delivery using Biojector

  • While Biojector delivery induced significant humoral and cellular immune responses, it did not significantly improve vaccine immunogenicity compared to conventional N/S delivery

  • Both methods elicited comparable Env-specific antibody responses regardless of whether it was a primary or secondary immunization

• Reactogenicity profile:

  • Biojector delivery of rAd5 vaccine was found to be well-tolerated, with a safety profile comparable to N/S delivery

• Impact of pre-existing immunity:

  • The mode of delivery did not affect the relationship between pre-existing Ad5 antibody titers and immune responses

  • Subjects with low pre-existing Ad5 antibodies showed modestly higher responses regardless of delivery method

These findings suggest that while Biojector delivery is a viable alternative to conventional needle and syringe, it does not offer significant immunological advantages for rAd5 vector vaccines.

What explains the differential effect of homologous boosting on antibody versus T cell responses?

A notable finding in rAd5 vaccine research is the differential impact of homologous boosting on antibody and T cell responses:

• Antibody responses: Homologous boosting with rAd5 vaccine substantially enhances Env-specific antibody responses (approximately 10-fold higher) compared to primary immunization, despite pre-existing vector immunity .

• T cell responses: In contrast, IFN-γ ELISpot responses and CD4+/CD8+ T cell responses evaluated at 4 weeks post rAd5 vaccine remained relatively low after boosting and showed minimal enhancement compared to primary immunization .

• Potential mechanisms: Several factors might explain this differential effect:

  • Different thresholds of vector-mediated antigen expression required for boosting antibody versus T cell responses

  • Differential impact of pre-existing vector immunity on antigen presentation pathways relevant to antibody versus T cell responses

  • Potential role of memory B cells versus T cells in response to booster immunizations

This observation has important implications for vaccination strategies, suggesting that homologous rAd5 boosting may be more effective for enhancing antibody responses than cellular immunity.

What study designs have been used to evaluate rAd5 vector vaccines?

Clinical evaluation of rAd5 vaccines has employed various study designs:

• Phase 1/2 safety and immunogenicity trials:

  • Randomized, double-blind, placebo-controlled designs

  • Dose-escalation studies to evaluate different concentrations (e.g., 10^10 vs. 10^11 particle units)

  • Stratification based on pre-existing Ad5 neutralizing antibody titers

• Prime-boost studies:

  • Comparison of different prime-boost intervals

  • Evaluation of homologous (rAd5-rAd5) versus heterologous (DNA-rAd5) prime-boost regimens

• Administration method comparisons:

  • Open-label designs comparing different delivery methods (Biojector vs. needle/syringe)

• Phase 2b efficacy trials:

  • Large-scale, multi-site randomized controlled trials with endpoints including HIV-1 acquisition and viral-load set point

  • Long-term follow-up (24+ months) to assess durability of responses and protection

These varied study designs allow for comprehensive evaluation of vaccine safety, immunogenicity, and efficacy across different populations and delivery strategies.

What populations have been included in rAd5 vector vaccine trials?

rAd5 vaccine trials have enrolled diverse populations based on study objectives:

• HVTN 505 efficacy trial:

  • Men and transgender women between ages 18-50 years

  • Fully circumcised individuals

  • History of unprotected anal intercourse with one or more male or male-to-female transgender partners, or anal intercourse with two or more such partners in the 6 months before randomization

  • Ad5 serum neutralizing antibody titer of less than 1:18

  • Conducted at 21 sites in the United States

• Additional eligibility considerations:

  • Ad5 serostatus (stratification by pre-existing Ad5 antibody levels)

  • Previous participation in rAd5 vaccine trials (for studies of homologous boosting)

  • Normal laboratory parameters including liver function tests

• International trials:

  • Some studies specifically targeted African populations to provide information about safety and immunogenicity in regions with different Ad5 seroprevalence profiles

These population selections reflect the targeted nature of HIV vaccine development efforts and the importance of evaluating vaccines in populations at increased risk for HIV-1 infection.

How are breakthrough infections analyzed in rAd5 HIV vaccine trials?

In HIV vaccine efficacy trials, breakthrough infections (HIV infections occurring despite vaccination) provide critical data:

• Viral load set point analysis:

  • Participants with confirmed HIV-1 infection are followed for viral load measurements

  • Plasma HIV-1 RNA levels are measured at multiple timepoints (10, 12, 14, 16, and 20 weeks after diagnosis)

  • These measurements are averaged to determine the mean viral-load set point

• Implications of set point analysis:

  • Lower viral set points have been associated with slower disease progression

  • Vaccine effects on viral load set point may indicate partial efficacy even without prevention of infection

• Additional analyses:

  • Genetic sequencing of breakthrough viruses to assess correlations between vaccine antigens and infecting strains

  • Neutralization sensitivity of breakthrough viruses

  • Correlation of breakthrough infections with pre-infection immune responses

These analyses help determine whether the vaccine shows any beneficial effects in recipients who become infected despite vaccination.

How does pre-exposure prophylaxis (PrEP) use affect the interpretation of rAd5 HIV vaccine trial results?

The introduction of pre-exposure prophylaxis (PrEP) has complicated the landscape of HIV vaccine trials:

As PrEP use increases in populations at risk for HIV, vaccine trials must carefully account for this confounding factor in design and analysis.

What lessons from rAd5 vaccine research apply to other adenoviral vector platforms?

While development of this specific rAd5 HIV vaccine has been discontinued due to lack of efficacy, several important lessons apply to other adenoviral vector vaccines:

• Vector immunity considerations:

  • Homologous boosting with adenoviral vectors can boost insert-specific antibody responses despite pre-existing vector immunity

  • This effect appears to persist regardless of the interval between prime and boost

• Administration methods:

  • Needle-free delivery systems like Biojector are well-tolerated but do not significantly improve immunogenicity compared to conventional needle and syringe delivery

• Alternative adenovirus serotypes:

  • Research has pivoted toward using rare human adenovirus serotypes or adenoviruses from other species to circumvent pre-existing immunity issues

  • This approach maintains the advantages of adenoviral vectors while addressing limitations of Ad5

• Applications beyond HIV:

  • The findings remain relevant to other vaccine platforms using recombinant adenoviral vectors for diseases such as malaria, leishmaniasis, Chagas disease, dengue, influenza, and Ebola

These insights continue to inform the development of next-generation adenoviral vector vaccines across multiple disease areas.

What immunological parameters might better predict vaccine efficacy than those currently measured?

Despite inducing measurable immune responses, the rAd5 HIV vaccines tested did not demonstrate protective efficacy, highlighting the need for better correlates of protection:

• Beyond magnitude of response:

  • Qualitative aspects of T cell responses, including polyfunctionality, proliferative capacity, and cytotoxic potential

  • Antibody quality measures including epitope specificity, avidity maturation, and Fc-mediated effector functions

• Tissue-resident immunity:

  • Assessment of mucosal immune responses at sites of potential HIV exposure

  • Tissue-resident memory T cells that may provide frontline defense

• Breadth of response:

  • Cross-clade neutralizing antibodies and broadly reactive T cell responses

  • Responses to conserved epitopes that may be less susceptible to viral escape

• Systems biology approaches:

  • Transcriptomic and metabolomic signatures that may predict response quality

  • Innate immune parameters that shape adaptive responses

Developing and validating these more sophisticated immunological parameters may improve the ability to predict which vaccine candidates are most likely to demonstrate efficacy in large-scale trials.